copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Bayesian Optimal Interval (BOIN) Design for Phase I Clinical Trials Perform cohort expansion on 3+3 to match the sample size of BOIN Match the sample size of BOIN to that of 3+3 Enter Simulation Scenarios Add a Scenario Remove a Scenario Save Scenarios Number of Simulations: Set Seed: For each scenario, enter true toxicity rate of each dose level:
Bayesian Optimal Interval Design: A Simple and Well-Performing Design . . . Despite more than two decades of publications that offer more innovative model-based designs, the classical 3 + 3 design remains the most dominant phase I trial design in practice In this article, we introduce a new trial design, the Bayesian optimal interval (BOIN) design The BOIN design is easy …
Trial Design U-BOIN is a utility-based seamless Bayesian phase I II trial design to find the optimal biological dose (OBD) for targeted and immune therapies It allows physicians to incorporate the risk-benefit trade-off to more realistically reflect the clinical practice
An overview of the BOIN design and its current extensions for novel . . . Bayesian Optimal Interval (BOIN) designs are a class of model-assisted dose-finding designs that can be used in oncology trials to determine the maximum tolerated dose (MTD) of a study drug based on safety or the optimal biological dose (OBD) based
BOIN: Bayesian Optimal INterval (BOIN) Design for Single-Agent and Drug . . . Description The Bayesian optimal interval (BOIN) design is a novel phase I clinical trial design for finding the maximum tolerated dose (MTD) It can be used to design both single-agent and drug-combination trials The BOIN design is motivated by the top priority and concern of clinicians when testing a new
Software Download Kiosk gt; BOIN Design Desktop Program Bayesian Optimal Interval (BOIN) Design Desktop Program The BOIN Design Program provides a novel platform for designing various phase I clinical trials, including single-agent and drug-combination trials, as well as trials with late-onset toxicity